Highland Investment Advisors’s AstraZeneca AZN Stock Holding History

Highland Investment Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$76.7K	Buy	+404	New	+$76K	0.03%	142

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Asset Management London, Ec4n 8af $148B AUM

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Prudential plc London, England, United Kingdom $18.4B AUM 23.98% 1-Year Est. Return

Highland Investment Advisors's AZN Position: Q2 2026 in Review

Highland Investment Advisors opened a new position in AstraZeneca (AZN) in Q2 2026: 404 shares worth $76.7K. The stake represents 0.03% of the portfolio and ranks #142 among its holdings.

1,425 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Highland Investment Advisors held 404 shares of AstraZeneca worth $76.7K as of Q2 2026.
AstraZeneca was a new Highland Investment Advisors position in Q2 2026.
AstraZeneca made up 0.03% of Highland Investment Advisors's portfolio in Q2 2026, its #142 holding.
1,425 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Highland Investment Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.